Clinical Study results on the influence
of ArtemiC Support® on patients
with Long COVID Syndrome
Key Highlights :
· Clinical Study demonstrates the ability of MGC Pharma’s ArtemiC Support® to reduce severe symptoms of Post-Acute COVID Syndrome (Long COVID).
· Study results demonstrate the statistically significant efficacy of ArtemiC Support® in reducing the severity of a range of Long COVID symptoms, including Dyspnea, Cough, Asthenia, Headache and Mental Confusion.
· 150 Patients were administered ArtemiC Support® during a 6-week period under the supervision of their doctor, with their progress measured against a Post-COVID Functional Scale (PCFS), and a 10-point Likert scale, one, two, three and 6 weeks after treatment initiation.
· It is estimated that over 50% of patients who recover from COVID-19 have persistent symptoms of Long COVID1.
MGC Pharmaceuticals Ltd (‘MGC Pharma’ or ‘the Company’) , a European based bio-pharma company specialising in the production and development of phytomedicines is pleased to announce the successful results of a clinical study into the influence of its propriety product, ArtemiC Support® , on patients with Post-Acute COVID Syndrome, also known as Long COVID.
Long COVID refers to the ongoing health problems that people can experience four or more weeks after being infected with SARS-COV-2, the virus responsible for COVID-19. Long COVID is believed to affect more than 50% of all COVID-19 patients1.
The clinical study, being sponsored by Swiss PharmaCan AG (‘SPC’) and is co-sponsored by MGC Pharma and Glow LifeTech Ltd, undertaken to obtain partial results on the effectiveness and safety of MGC Pharma’s, ArtemiC Support® , has demonstrated the ability of the supplement to improve the symptoms of Long COVID.
The Study, undertaken in conjunction with primary care clinicals in Barcelona, CAP Can Bou and Sardenya EAP, was an open label study, commencing with six-weeks of treatment with ArtemiC Support®. The Study’s objectives were to assess the safety and efficacy of ArtemiC Support® in Long COVID patients by measuring the symptoms’ severity using a Post-COVID Functional Scale (PCFS).
The study enrolled 150 patients suffering from Long COVID who administered ArtemiC Support® , an Oral Spray, for 6 weeks under supervision of their doctor, with their progress being measured using a Post-COVID Functional Scale (PCFS) and a 10-point Likert scale 1, 2, 3 and 6 weeks after treatment initiation. The symptoms measured include:
1. Dyspnea – shortness of breath
2. Asthenia – abnormal physical weakness or lack of energy
3. Anosmia – loss of senses of smell
4. Ageusia – loss of sense of taste
5. Cough
6. Headache
7. Mental confusion
1. https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003773
The results of the study demonstrated Artemic Support® statistically significant efficacy in reducing the severity of a number of Long COVID symptoms, including Dyspnea, Cough, Asthenia, Headache and Mental Confusion.
Artemic Support® is the second product in the Company’s ArtemiCTM product range to progress to the Clinical Trial phase to determine safety and efficacy against SARS2-COV-2 related diseases. In 2020 the Company completed a Phase II Clinical Trial which demonstrated ArtemiCTM’s safety and efficacy in treating patients diagnosed with moderate COVID-19. (refer ASX Announcement dated 15 December 2020)
The graphs show the Emmean (Estimated Marginal Mean) observed results from data collected during the Artemic Support® Long COVID study
http://www.rns-pdf.londonstockexchange.com/rns/4645S_1-2022-7-14.pdf
About ArtemiCTM
ArtemiC™ is a clinically tested food supplement (nutraceutical, dietary supplement, natural health product) containing natural based ingredients. The nutraceutical, developed by MGC Pharma, incorporates Swiss PharmaCan AG’s award winning MyCellTM technology, which increases the bioavailability of ArtemiCTM’s active ingredients at cell level.
In a Phase II double-blind, placebo-controlled Clinical Trial on 50 patients with COVID-19, ArtemiC demonstrated the following advantages:
· A full safety and efficacy profile with no drug-adverse events
· The ability to prevent deterioration of COVID-19 patients and achieve faster clinical improvement
· The ability to assist in reducing the pressure on the medical system and support coping with hospitalised patients
· The ability to reduce symptoms and pain associated with COVID-19
· The versatility to be used in community setting as well as in hospitals
Roby Zomer, Co-founder and Managing Director of MGC Pharma, commented: “The results of this trial represent a real breakthrough for the Company, and are another step forward in demonstrating the ArtemiC range of product’s efficacy in treating patients suffering from both COVID-19 and Long COVID.
“Given previous trials, we were optimistic that ArtemiC would prove effective in the current trials, however it is this extremely gratifying to see this born out in a clinical trial undertaken by a Third Party, and we are all very excited about the results and what this means for making our products available to patients who have been suffering with COVID-19 and related diseases for far too long”
About MGC Pharma
MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytomedicines to patients globally. The Company’s founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions – Epilepsy and Dementia – and has further products in the development pipeline.
Employing its ‘Nature to Medicine’ strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company’s EU-GMP Certified manufacturing facility.
MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.
MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.
Follow us through our social media channels:
Twitter: @MGC_Pharma
Facebook: @mgcpharmaceuticals
LinkedIn: MGC Pharmaceuticals Ltd.
Instagram: @mgc_pharma
